Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SGMT
SAGIMET BIOSCIENCES INC.
NASDAQ
$10.55
▼ DOWN 1.86% (-0.20)

KEY STATISTICS

Market Cap$343.74 M
52w High$11.15
52w Low$4.50
Dividend Yield—
Frequency—
P/E-7.87
Volume573.99K
Shares Out.32.58M

COMPANY

LEADERSHIP

David A. Happel
CHIEF EXECUTIVE
David A. Happel

COMPENSATION 2026

Salary$630,000
Stock Awards$546,360
Incentive Plan Pay$294,525
All Other Comp.$19,358
Total$3,239,994

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 14, 2023
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
16

PRICE TARGET

Target High$8.00
Target Low$6.00
Target Median$7.00
Target Consensus$7.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$166.67K
NOV
12
THU

PRICE

$10.55 ▼ DOWN 1.86% (−$0.20)
$10.50$10.60$10.70$10.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM10.55

About Sagimet Biosciences Inc.

https://www.sagimet.com ↗

Sagimet Biosciences Inc., a clinical-stage biotech in San Mateo, develops FASN inhibitors like Denifanstat for NASH, acne, and cancers, focusing on diseases caused by lipid metabolism dysfunction.

INDUSTRY

Biotechnology

A PRODUCT SAGIMET BIOSCIENCES INC. IS KNOWN FOR

Denifanstat
Denifanstat

Denifanstat, Sagimet Biosciences' lead oral FASN inhibitor, is in clinical development for MASH and has shown positive Phase 3 results for moderate to severe acne in China.

COMPETITORS

COMPETITOR
IVA COMPARE
MDGL COMPARE
VKTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
70
LISTED HERE
11
RANKED BY POSITION SIZE
VTI
0.00% · 1.9M
IWM
0.02% · 1.5M
XBI
0.09% · 1.0M
DFAS
0.01% · 136.6K
XRSG.L
0.02% · 53.8K
LABU
0.06% · 38.1K
RSSL
0.02% · 27.8K
IBBQ
0.04% · 3.8K
URTY
0.01% · 2.4K
PWS
0.02% · 456
RESM
0.02% · 115

INSTITUTIONAL OWNERSHIP

SHARES OWNED
36.49%
HOLDERS
114
TOP 12 OF 114 · RANKED BY POSITION SIZE
Woodline Partners LP
1.5M sh · $10.3M
Blue Owl Capital Holdings LP
1.3M sh · $9.11M
Vanguard Group Inc
1.3M sh · $7.46M
Affinity Asset Advisors, LLC
1.1M sh · $6.8M
Marshall Wace, Llp
966.3K sh · $5.04M
Baker Bros. Advisors LP
953.0K sh · $4.98M
Blackrock Inc.
904.1K sh · $3.09M
Millennium Management LLC
862.3K sh · $4.51M
Blackrock, Inc.
814.0K sh · $4.82M
Hhlr Advisors, Ltd.
724.8K sh · $3.79M
Siren, L.L.C.
724.8K sh · $4.29M
D. E. Shaw & Co., Inc.
701.2K sh · $4.81M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Kemble George
Sale · 326.6K shares
2026-08-14
★
DIRECTOR
Kemble George
Sale · 24.4K shares
2026-08-14
★
DIRECTOR
Kemble George
Purchase · 326.6K shares
2026-08-14
★
DIRECTOR
Kemble George
Sale · 351.0K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
MARKET OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM Canaccord Genuity BUY Guggenheim BUY

SECTORS PEERS

PEERPRICE
ACHV$8.10COMPARE
ASMB$34.07COMPARE
ZURA$5.72COMPARE
ARCT$15.19COMPARE
AVIR$5.36COMPARE
FHTX$6.00COMPARE
TRDA$7.00COMPARE
VYGR$3.54COMPARE